Skyline Medical Inc. — Q2 2015 Form 10-Q
Entity note: The request identifies Axe Compute Inc., but the supplied filing is for Skyline Medical Inc. This summary reflects the filing provided. Reporting period ended June 30, 2015; filed August 10, 2015. Amounts are in U.S. dollars.
Business context and reporting period
Skyline Medical is a development-stage medical-device company selling the STREAMWAY system for collecting and disposing of surgical fluids, plus related cleaning fluid and filters. The unaudited results cover the three and six months ended June 30, 2015, with comparisons to 2014.
Financial results and liquidity
- Revenue: Q2 revenue was $234,012, down 26% from $318,293. First-half revenue was $385,286, down slightly from $388,513. First-half 2015 revenue included 14 STREAMWAY systems and disposable sales totaling approximately $154,000.
- Gross profit and margin: Q2 gross profit was $150,446, a 64% margin, versus $219,928 and 69% a year earlier. First-half gross profit was $205,752, a 53% margin, versus $259,065 and 67% in 2014. Management attributed lower first-half margins partly to replacing earlier systems at no charge.
- Net loss: Q2 net loss attributable to common shareholders was $1.185 million, versus $1.736 million. First-half net loss was $1.411 million, versus $3.353 million. Basic and diluted loss per share was $0.36 for Q2 and $0.44 for the first half, compared with $0.58 and $1.13, respectively, in 2014.
- Expenses and interest: First-half interest expense rose to $342,837 from $32,897, primarily reflecting convertible-note interest and debt-discount amortization. The statements report first-half general and administrative expense of $728,424, but report Q2 expense of $856,219; those figures do not reconcile, so the filing text does not provide a clear comparable period breakdown.
- Cash flow: First-half cash used in operations was $214,581, compared with $1.947 million in 2014. Investing activities used $7,700; financing provided $250,000, from convertible notes. Cash increased by $27,719 to $44,103.
- Balance sheet and liquidity: At June 30, cash was $44,103 and current assets were $520,217, versus current liabilities of $6.890 million, implying a working-capital deficit of approximately $6.369 million. Total assets were $745,455; total liabilities were $6.890 million; stockholders’ deficit was $6.144 million.
- Debt and obligations: Short-term convertible notes were reported at $933,074. Accounts payable were $2.474 million and accrued expenses $3.474 million. Management said approximately $6.890 million of debts, liabilities and cash obligations were past due or due during 2015.
Material changes versus the prior comparable period
- First-half revenue was nearly flat year over year, while first-half gross margin fell from approximately 67% to 53%.
- First-half net loss and operating cash use were lower than in 2014. Management cited lower spending and vendor-payment timing, inventory reductions, and the absence of some prior-year settlement, financing, compensation and sales-staff costs.
- Interest expense increased substantially as convertible-note financing and related discounts affected results.
- Cash remained very limited despite $250,000 of first-half note proceeds; cash at period end was $44,103.
Outlook, risks and unusual items
- Going concern: The company reported recurring operating losses and a stockholders’ deficit, and stated there was substantial doubt about its ability to continue as a going concern. It anticipated losses at least through 2015 and described monthly expenses of approximately $250,000.
- Financing plans: In July 2015, the company filed a registration statement for a proposed public offering of units and said it intended to pursue a NASDAQ listing. The filing does not establish that the offering would close or provide sufficient proceeds.
- Convertible-note redemption: Noteholders agreed to forgo conversion rights in exchange for redemption after the proposed offering at 140% of principal plus accrued interest; the company estimated total redemption payments of approximately $1.4 million. The agreement and payment depend on the offering.
- Management outlook: Management expected margins to improve with more consistent production and volume purchasing discounts, and expected revenue growth to outpace related cost growth over coming quarters. It also said sales depend on hospital approvals and customer orders; no quantified revenue guidance was provided.
- Funding and operating risks: The company had delayed payments to vendors and service providers and warned that inadequate financing could limit operations, disrupt supplies, trigger creditor claims, or lead to restructuring or cessation of business. Additional financing could be highly dilutive or contain onerous terms.
- Legal matters: A settlement with former product engineer Marshall Ryan was extended in April 2015, adding $50,000 and 18% interest to the balance, with specified payment and funding-trigger provisions. Four current or former sales managers filed a compensation-related lawsuit in April 2015; the company acknowledged that certain amounts were owing and said it intended to defend the claims.
- Other items: Common shares outstanding were 3,312,863 as of August 6, 2015. The company disclosed no material change in risk factors other than the updated financing/going-concern risk. Management concluded disclosure controls were effective as of June 30, 2015.
Key facts investors should verify
- Confirm the registrant identity: the supplied filing is Skyline Medical Inc., not Axe Compute Inc.
- Check the general and administrative expense figures: the reported Q2 amount exceeds the reported first-half amount, and the filing text does not clearly reconcile them.
- Verify whether the proposed public offering and NASDAQ listing were completed, the proceeds raised, and whether they funded operations and note redemption.
- Assess the timing and status of the approximately $1.4 million note redemption, the Ryan settlement payments, and other overdue obligations.
- Track sales of STREAMWAY systems, hospital adoption and trials, gross margins, and cash runway against management’s stated expectations.
- Review dilution exposure from outstanding convertible securities, options and warrants, and the proposed preferred-stock exchange.